Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

Por Kanada, Shigeto, Koiwai, Kazuki, Taniguchi, Atsushi, Sarashina, Akiko, Seman, Leo, Woerle, Hans J
Publicado em 2013

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

Por Heise, Tim, Seman, Leo, Macha, Sreeraj, Jones, Peter, Marquart, Alexandra, Pinnetti, Sabine, Woerle, Hans J., Dugi, Klaus
Publicado em 2013

Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

Por Riggs, Matthew M, Seman, Leo J, Staab, Alexander, MacGregor, Thomas R, Gillespie, William, Gastonguay, Marc R, Woerle, Hans J, Macha, Sreeraj
Publicado no Br J Clin Pharmacol (2014)

Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study

Por Lamon-Fava, Stefania, Marcovina, Santica M., Albers, John J., Kennedy, Hal, DeLuca, Carl, White, Charles C., Cupples, L. Adrienne, McNamara, Judith R., Seman, Leo J., Bongard, Vanina, Schaefer, Ernst J.
Publicado em 2011